-
Mashup Score: 12
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both…
Source: www.sciencedirect.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 12
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both…
Source: www.sciencedirect.comCategories: General Medicine News, Partners & KOLsTweet-
RT @ldandersonjr: CAR T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the #ASTCT https://t.co/hZvsZczF3H @MediHumda…
-
-
Mashup Score: 12
The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both…
Source: www.sciencedirect.comCategories: General Medicine News, Partners & KOLsTweet-
RT @ldandersonjr: CAR T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the #ASTCT https://t.co/hZvsZczF3H @MediHumda…
-
-
Mashup Score: 0Nurse Researchers Make The Case For “Real-Time Toxicity” Teams in Bone Marrow Transplantation - 1 year(s) ago
Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation. #BMT #toxicity #oncolgoy #nursing #ASTCT @MSKCancerCenter https://t.co/2fOsmGyv1W
-
-
Mashup Score: 0Nurse Researchers Make The Case For “Real-Time Toxicity” Teams in Bone Marrow Transplantation - 1 year(s) ago
Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nurse Researchers Make The Case For “Real-Time Toxicity” Teams in Bone Marrow Transplantation #BMT #toxicity #oncolgoy #nursing #ASTCT @MSKCancerCenter https://t.co/8CPsYgVCLB
-
-
Mashup Score: 0
Adults with advanced multiple myeloma and renal insufficiency treated with idecabtagene vicleucel achieved similar outcomes as those with normal renal function, according to retrospective study results.A single dose of the chimeric antigen receptor T-cell therapy presents no additional risk for treatment-related toxicities among patients with renal insufficiency, findings presented at Tandem
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-T safe, effective for adults with multiple myeloma and renal insufficiency. https://t.co/pecG7CStOC #NextCellTherapy #Tandem23 @ASTCT #ASTCT #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Targeted conditioning with iodine (131I) apamistamab enabled older patients with relapsed or refractory acute myeloid leukemia to undergo allogeneic hematopoietic stem cell transplantation, according to results of the phase 3 SIERRA trial.The findings, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, showed iodine (131I) apamistamab, known
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML. https://t.co/FlprapiUIQ #Tandem23 @ASTCT #ASTCT #HemOnc #OncAlert #MedEd @MSKCancerCenter
-
-
Mashup Score: 0Vedolizumab may help prevent lower GI acute GVHD after unrelated stem cell transplant - 1 year(s) ago
Vedolizumab showed greater efficacy than placebo when added to standard prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, according to a study.The initial findings of the GRAPHITE trial, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, also showed
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Vedolizumab may help prevent lower GI acute GVHD after unrelated stem cell transplant. https://t.co/ynRG74OMLe #Vedolizumab #Tandem23 @ASTCT #ASTCT #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Outpatient hematopoietic stem cell transplantation following targeted antibody-based conditioning appeared safe and feasible among older patients with acute myeloid leukemia or myelodysplastic syndrome, according to study results.The findings, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, indicated that outpatient HSCT using the
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome. https://t.co/Wa9Y7pSRjF #Tandem23 @ASTCT #ASTCT #HemOnc #OncAlert #MedEd @StanfordMed
-
-
Mashup Score: 12023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - 1 year(s) ago
Sign In My TimeEST …
Categories: Hem/Oncs, Latest HeadlinesTweet-
Attending #Tandem23 and interested in Lab Science make sure to join new @ASTCT Laboratory Science SIG led by @AlanHanash @kean_leslie, help shape #ASTCT scientific initiatives & support of scientists in BMT/CT 2-3 PM Friday Feb 17 Magnolia 12 https://t.co/gUOHdlf9ek
-
RT @ldandersonjr: CAR T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the #ASTCT https://t.co/hZvsZczF3H @MediHumda…